UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 8, 2011
Bio-Reference Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
New Jersey |
|
0-15266 |
|
22-2405059 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
481 Edward H. Ross Drive, Elmwood Park, |
|
NJ 07407 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(201) 791-2600
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14-d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Bio-Reference Laboratories, Inc.
Form 8-K
September 8, 2011
Item 5.07 Submission of Matters to a Vote of Security Holders
(a) The annual stockholder meeting of Bio-Reference Laboratories, Inc. (the “Company”) was held on September 8, 2011
(b) (1) At the meeting, Sam Singer and Harry Elias were elected by the following votes, each to serve as the two Class II directors of the Company for a term of three years.
|
|
|
FOR |
|
Authority Withheld |
|
|
Sam Singer |
|
17,534,409 |
|
3,698,513 |
|
|
Harry Elias |
|
19,863,441 |
|
1,369,481 |
|
(b) (2) At the meeting, stockholders approved, on an advisory basis, the compensation paid to the Company’s three executive officers as disclosed in the annual meeting Proxy Statement. The vote was as follows:
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
|
13,393,031.0 |
|
6,853,122 |
|
986,769 |
|
(b) (3) At the meeting, stockholders voted on an advisory basis, that the frequency with which the Company’s stockholders should have an advisory vote on executive compensation of the Company’s named executive officers should be as follows:
|
|
|
FOR |
|
|
|
|
Every year |
|
12,963,290 |
|
|
|
|
Every two years |
|
1,581,157 |
|
|
|
|
Every three years |
|
6,479,180 |
|
|
|
|
Abstain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Abstain |
|
|
|
|
|
|
209,295 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
Bio-Reference Laboratories, Inc. |
|
|
(Registrant) |
|
|
|
|
|
/s/ Sam Singer |
|
|
Sam Singer |
|
|
Senior Vice President and |
|
Date: September 8, 2011 |
Chief Financial Officer |